Cagrilintide vs Retatrutide
How Cagrilintide and Retatrutide compare on research category, evidence tier, regulatory status, and reported side effects.
The verdict
Both are next-generation metabolic peptides in active trials, but they work differently. Cagrilintide is a long-acting amylin analog often studied alongside semaglutide, while Retatrutide is a triple agonist (GLP-1, GIP, glucagon) posting some of the largest weight-loss figures reported so far. Neither is FDA-approved yet. Retatrutide has the bigger standalone effect-size headlines; Cagrilintide's story is mostly as a combination partner. Both are ones-to-watch, not settled options.
Cagrilintide is an amylin agonist, a different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' for weight loss that breaks past GLP-1 plateaus. Once-weekly injection.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Cagrilintide if users plateaued on semaglutide or tirzepatide or people wanting cleaner satiety without bigger glp-1 nausea.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Cagrilintide and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.